Clinical OutcomesAn overall response rate of 97% was observed, with 62% of patients achieving a complete response or better.
Market DifferentiationThe opportunity for anito-cel to commercialize through Kite manufacturing, with a quick turnaround time, is seen as a differentiator in the commercial market.
Safety And EfficacyAnito-cel has demonstrated superior safety, as exemplified by a lack of delayed neurotoxicity events to date.